1α(OH)D3 one-alpha-hydroxy-cholecalciferol - An active vitamin D analog

Danish Medical Bulletin

Volumn 55, Issue 4, 2008, Pages 186-210

  Brandi, Lisbet ^a,b  

^a Rigshospitalet   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALFACALCIDOL; ALUMINUM SALT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLECALCIFEROL DERIVATIVE; DOXERCALCIFEROL; FALECALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; VITAMIN D; VITAMIN D RECEPTOR;

AREA UNDER THE CURVE; BONE BIOPSY; CALCIUM HOMEOSTASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOGENESIS; PHOSPHATE METABOLISM; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; UREMIA; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; INTESTINE ABSORPTION; METABOLISM;

CALCITRIOL; CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; UREMIA;

EID: 62949153123     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Review

References (339)

1. Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K: Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 1989;53:194-200.
2. Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, Olgaard K: Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992;12:311-318.
3. Brandi L, Daugaard H, Egsmose C, Tvedegaard E, Kjaerulff NP, Olgaard K: Intermittent intravenous followed by intermittent oral 1 alpha (OH)D3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med 1996;239:353-360.
4. 3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996;74:89-103.
5. Brandi L, Nielsen PK, Bro S, Daugaard H, Olgaard K: Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. J Intern Med 1998;244: 121-131.
6. Brandi L, Egfjord M, Olgaard K: Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant 2002;17:829-842.
7. Brandi L, Egfjord M, Olgaard K: Comparison between 1alpha(OH)D(3) and 1,25(OH)(2)D(3) on the Suppression of Plasma PTH Levels in Uremic Patients, Evaluated by the 'Whole' and 'Intact' PTH Assays. Nephron Clin Pract 2005;99:c128-c137.
8. Shampo MA, Kyle RA: Adolf Windaus - Nobel Prize for research on sterols. Mayo Clin Proc 2001;76:119.
9. Nicolaysen, R. Studies upon the mode of action of vitamin D III. The influence of vitamin D on the absorption of calcium and phosphorous in the rat. Biochem.J. 122-129. 1937.
10. Carlsson A: Tracer experiments on the effect of vitamin D on the skeletal metabolism of calcium and phosphorus. Acta Physiol Scand 1952; 26:212-220.
11. Garabedian M, Tanaka Y, Holick MF, DeLuca HF: Response of intestinal calcium transport and bone calcium mobilization to 1,25-dihydroxyvitamin D3 in thyroparathyroidectomized rats. Endocrinology 1974;94: 1022-1027.
12. Yamamoto M, Kawanobe Y, Takahashi H, Shimazawa E, Kimura S, Ogata E: Vitamin D deficiency and renal calcium transport in the rat. J Clin Invest 1984;74:507-513.
13. Kodicek, E. The metaboliam of vitamin D. Proceedings of the fourth International Congress of biochemistry. Umbreit, W. and Molitor, H. (11), 198-208. 1960. London, Pergamon.
14. Lund J, DeLuca HF: Biologically active metabolite of vitamin D3 from bone, liver, and blood serum. J Lipid Res 1966;7:739-744.
15. Blunt JW, DeLuca HF, Schnoes HK: 25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 1968;7:3317-3322.
16. DeLuca, H. F. Metabolism and function of vitamin D in The Fat Soluble Vitamins. DeLuca, H. F. and Suttie, J. W. 3-20. 1970. Madison, Univ. of Wisconsin Press.
17. Fraser DR, Kodicek E: Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970;228:764-766.
18. Holick MF, Schnoes HK, DeLuca HF: Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci U S A 1971;68:803-804.
19. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF: Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 1973;289: 817-822.
20. Semmler, E. J., Holick, M. F., Schnoes, H. K., and DeLuca, H. F. The synthesis of 1a,25-dihydroxycholecalciferol - a metabolically active form of vitamin D3. Tetrahedron Letters 40, 4147-1972.
21. Paaren, H. E., Schnoes, H. K., and DeLuca, H. F. Synthesis of 1b-hydroxyvitamin D3 and 1b,25-dihydroxyvitamin D3. J.Chem.Soc.Chem. Commun. 890-892. 1977.
22. Mawer EB, Taylor CM, Backhouse J, Lumb GA, Stanbury SW: Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1973;1:626-628.
23. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55:1019-1027.
24. Zull JE, Czarnowska-Misztal E, DeLuca HF: On the relationship between vitamin D action and actinomycin-sensitive processes. Proc Natl Acad Sci U S A 1966;55:177-184.
25. Brumbaugh PF, Haussler MR: 1Alpha,25-dihydroxyvitamin D3 receptor: competitive binding of vitamin D analogs. Life Sci 1973;13:1737-1746.
26. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988;85:3294-3298.
27. Brown AJ, Dusso A, Slatopolsky E: Vitamin D. Am J Physiol 1999;277: F157-F175.
28. Bouillon R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C: Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. Eur J Endocrinol 1995;133:7-16.
29. Boyan BD, Dean DD, Sylvia VL, Schwartz Z: Nongenomic regulation of extracellular matrix events by vitamin D metabolites. J Cell Biochem 1994;56:331-339.
30. Norman, A. W. Rapid biological responses mediated by 1a,25-dihydroxyvitamin D3:A case study of transcaltachia. In:Vitamin D. Feldman, D., Glorieux, F. H., and Pike, J. W. 233-256. 1997. San Diego, CA, USA, Academic press.
31. Ramasamy I: Recent advances in physiological calcium homeostasis. Clin Chem Lab Med 2006;44:237-273.
32. Baker SB, Worthley LI: The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc 2002;4:301-306.
33. Brown, E. M. The physiology of calcium metabolism. Becker, K. L. The principles and practice of endocrinology and metabolism. 2001. Philadelphia PA: Lippincott Williams & Wilkins.
34. Schwarz P, Madsen JC, Rasmussen AQ, Transbol I, Brown EM: Evidence for a role of intracellular stored parathyroid hormone in producing hysteresis of the PTH-calcium relationship in normal humans. Clin Endocrinol (Oxf) 1998;48:725-732.
35. Takeda E, Yamamoto H, Nashiki K, Sato T, Arai H, Taketani Y: Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 2004;8:191-200.
36. Prie D, Beck L, Urena P, Friedlander G: Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005;14:318-324.
37. Murer H, Hernando N, Forster I, Biber J: Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000;80:1373-1409.
38. Gupta A, Tenenhouse HS, Hoag HM, Wang D, Khadeer MA, Namba N, Feng X, Hruska KA: Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice. Bone 2001;29:467-476.
39. Tenenhouse HS, Martel J, Gauthier C, Segawa H, Miyamoto K: Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol 2003;285:F1271-F1278.
40. Xu H, Bai L, Collins JF, Ghishan FK: Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics 1999;62:281-284.
41. Hilfiker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J: Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci U S A 1998;95:14564-14569.
42. Yu X, White KE: FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005;16:221-232.
43. Razzaque MS, Lanske B: Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006;12:298-305.
44. Kuro-o M: Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15:437-441.
45. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281: 6120-6123.
46. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG: The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005;310:490-493.
47. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima Y, Takeshige K, Kamiya T: The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001;131:3182-3188.
48. Lathrop F.W.: Renal Dwarfism: Report of case. Arch Intern Med 1926;38:612-622.
49. Langmead FS, Orr JW: Renal rickets associated with parathyroid hyperplasia. Arch Dis Child 1933;8:265-278.
50. Liu SH, Chu HI: Studies of calcium and phosphorous metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A.T.10) and iron. Medicine 1943;2:103-161.
51. Albright, F. and Reifenstein, E. C. jr. The parathyroid Glands and metabolic bone disease: Selected studies. 115-121. 1948. Baltimore, Williams & Wilkins.
52. Fourman, P., Royer, P, and Level, M. J. Calcium Metabolism and the bone. 2, 415-430. 1968. Oxford, Blackwell.
53. Morgan, B. Osteomalacia, Renal osteodystrophy and Osteoporosis. 224-231. 1973. Springfield, Thomas.
54. Curtis BM, Parfrey PS: How can the cardiac death rate be reduced in dialysis patients? Semin Dial 2002;15:22-24.
55. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
56. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
57. Moe SM: Vascular calcification: Hardening of the evidence. Kidney Int 2006;70:1535-1537.
58. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am.J.Kidney Dis. 42(suppl 3), 1-202. 2003.
59. Habener JF: Regulation of parathyroid hormone secretion and biosynthesis. Annu Rev Physiol 1981;43:211-223.
60. Habener, J. F. and Potts, J. T. jr. Metabolic Bone Disease. Avioli, L. V. and Krane, S. M. 69-130. 1990. Philadelphia, PA, Saunders.
61. Bell O, Silver J, Naveh-Many T: Identification and characterization of cis-acting elements in the human and bovine PTH mRNA 3′-untranslated region. J Bone Miner Res 2005;20:858-866.
62. Moallem E, Kilav R, Silver J, Naveh-Many T: RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998;273:5253-5259.
63. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB: Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876-881.
64. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14-S19.
65. Silver J, Kilav R, Naveh-Many T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002;283:F367-F376.
66. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-580.
67. Kifor O, Moore FD, Jr., Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM: Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-1606.
68. Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K: Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 2002;13:2110-2116.
69. Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-1056.
70. Rodriguez M, Nemeth E, Martin D: The calcium-sensing receptor - a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2004.
71. Mendes V, Jorgetti V, Nemeth J, Lavergne A, Lecharpentier Y, Cournot-Witmer G, Dubost C, Bourdon R, Bourdeau A, Zingraff J: Hyperparathyroidism secondary to renal insufficiency: anatomo-clinical relations and the potential role of an aluminum overload. Nephrologie 1984;5: 65-70.
72. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986;78:1296-1301.
73. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 1985;82:4270-4273.
74. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
75. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-1443.
76. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-1152.
77. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973;4:141-145.
78. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez CL, Campistol JM, Torres A, Rodriguez M: High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9:1845-1852.
79. Nielsen PK, Feldt-Rasmussen U, Olgaard K: A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 1996; 11:1762-1768.
80. Almaden Y, Felsenfeld AJ, Rodriguez M, Canadillas S, Luque F, Bas A, Bravo J, Torregrosa V, Palma A, Ramos B, Sanchez C, Martin-Malo A, Canalejo A: Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int 2003;64:2311-2317.
81. Almaden Y, Canalejo A, Ballesteros E, Anon G, Canadillas S, Rodriguez M: Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol 2002;13:693-698.
82. Afonso S, Santamaria I, Guinsburg ME, Gomez AO, Miranda JL, Jofre R, Menarguez J, Cannata-Andia J, Cigudosa JC: Chromosomal aberrations, the consequence of refractory hyperparathyroidism: its relationship with biochemical parameters. Kidney Int Suppl 2003;S32-S38.
83. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H: Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1996;20:744-750.
84. Chudek J, Ritz E, Kovacs G: Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res 1998;4:211-214.
85. Slatopolsky E, Gonzalez E, Martin K: Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003;21:318-326.
86. Coen G: Adynamic bone disease: an update and overview. J Nephrol 2005;18:117-122.
87. Parfitt AM: Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003;12:387-403.
88. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-1093.
89. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993;44:1071-1077.
90. Chazan JA, Libbey NP, London MR, Pono L, Abuelo JG: The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Clin Nephrol 1991;35:78-85.
91. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in endstage renal failure - an evolving disorder. Kidney Int 1993;43:436-442.
92. Canavese C, Barolo S, Gurioli L, Cadario A, Portigliatti M, Isaia G, Thea A, Marangella M, Bongiorno P, Cavagnino A, Peona C, Boero R, D'Amicone M, Cardelli R, Rossi P, Piccoli G: Correlations between bone histopathology and serum biochemistry in uremic patients on chronic hemodialysis. Int J Artif Organs 1998;21:443-450.
93. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, Manni M, Mantella D, Mazzaferro S, Napoletano I, Sardella D, Taggi F: Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998;13:2294-2302.
94. Araujo SM, Ambrosoni P, Lobao RR, Caorsi H, Moyses RM, Barreto FC, Olaizola I, Cruz EA, Petraglia A, Dos Reis LM, Duarte ME, Jorgetti V, Carvalho AB: The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl 2003;S54-S56.
95. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, De Bonis E, Darias E, Gonzalez-Posada JM: Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47:1434-1442.
96. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone over-estimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-150.
97. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844.
98. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996;11:813-819.
99. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, Giustini M, Giordano R, Nicolai G, Manni M, Sardella D, Taggi F: Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002;91:103-111.
100. Urena P, De Vernejoul MC: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999;55:2141-2156.
101. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC: Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003;41:997-1007.
102. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E: Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003;60 Suppl 1:S13-S21.
103. Goldsmith D, Ritz E, Covic A: Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004;66:1315-1333.
104. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-1793.
105. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
106. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
107. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
108. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
109. Raggi P, Bommer J, Chertow GM: Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004;13:134-141.
110. Shanahan CM: Vascular calcification. Curr Opin Nephrol Hypertens 2005;14:361-367.
111. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-647.
112. Chen NX, O'Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
113. Giachelli CM: Mechanisms of vascular calcification in uremia. Semin Nephrol 2004;24:401-402.
114. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 1998;98: 1302-1306.
115. Rebsamen MC, Sun J, Norman AW, Liao JK: 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91:17-24.
116. Norman PE, Powell JT: Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol 2005;25:39-46.
117. Reinhart GA: Vitamin D analogs: novel therapeutic agents for cardiovascular disease? Curr Opin Investig Drugs 2004;5:947-951.
118. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81.
119. Chow KM, Szeto CC, Kum LC, Kwan BC, Fung TM, Wong TY, Leung CB, Li PK: Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. J Nephrol 2003;16:878-885.
120. Sato S, Ohta M, Kawaguchi Y, Okada H, Ono M, Saito H, Utsunomiya M, Tamura T, Sugimoto K, Takamizawa S,.: Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995;21:67-71.
121. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
122. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
123. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 1972;2:147-151.
124. Goldsmith RS, Furszyfer J, Johnson WJ, Fournier AE, Sizemore GW, Arnaud CD: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibility. J Clin Invest 1973;52:173-180.
125. Spalding EM, Chamney PW, Farrington K: Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int 2002;61:655-667.
126. Llach F: Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995;25:663-679.
127. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
128. Wills MR, Savory J: Aluminum and chronic renal failure: sources, absorption, transport, and toxicity. Crit Rev Clin Lab Sci 1989;27:59-107.
129. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-161.
130. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D: The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991;6:170-175.
131. Wallot M, Bonzel KE, Winter A, Georger B, Lettgen B, Bald M: Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 1996;10:625-630.
132. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
133. Salusky IB, Goodman WG: Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002;17:336-339.
134. Plone MA, Petersen JS, Rosenbaum DP, Burke SK: Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002;41:517-523.
135. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR: Bile acid binding to sevelamer HCl. Kidney Int 2002;62:611-619.
136. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307.
137. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14: 2907-2914.
138. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
139. Finn WF, Joy MS: A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005;21:657-664.
140. Chiang SS, Chen JB, Yang WC: Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-470.
141. Hergesell O, Ritz E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999;14:863-867.
142. Peerce BE, Clarke R: A phosphorylated phloretin derivative. Synthesis and effect on intestinal Na(+)-dependent phosphate absorption. Am J Physiol Gastrointest Liver Physiol 2002;283:G848-G855.
143. Peerce BE, Weaver L, Clarke RD: Effect of 2′-phosphophloretin on renal function in chronic renal failure rats. Am J Physiol Renal Physiol 2004;287:F48-F56.
144. Holick MF, Semmler EJ, Schnoes HK, DeLuca HF: 1-Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25-dihydroxyvitamin D 3. Science 1973;180:190-191.
145. Barton DH, Hesse RH, Pechet MM, Rizzardo E: A convenient synthesis of 1 -hydroxy-vitamin D 3. J Am Chem Soc 1973;95:2748-2749.
146. Russell J, Lettieri D, Sherwood LM: Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986;119:2864-2866.
147. Naveh-Many T, Silver J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-1319.
148. Madsen S, Olgaard K, Ladefoged J: Suppressive effect of 1,25-dihydroxy-vitamin D3 on circulating parathyroid hormone in acute renal failure. J Clin Endocrinol Metab 1981;53:823-827.
149. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988;34:840-844.
150. Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A: Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis 1988;12:487-491.
151. Martis L, Serkes KD, Nolph KD: Calcium carbonate as a phosphate binder: is there a need to adjust peritoneal dialysate calcium concentrations for patients using CaCO3? Perit Dial Int 1989;9:325-328.
152. Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z: Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987;28:222-226.
153. Dusso AS, Thadhani R, Slatopolsky E: Vitamin D receptor and analogs. Semin Nephrol 2004;24:10-16.
154. Wu-Wong JR, Tian J, Goltzman D: Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs 2004;5:320-326.
155. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432.
156. Goldenberg MM: Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999;21:432-441.
157. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
158. Barton PA, Lin S, Arruda JA, Lau AH: Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients. Int J Artif Organs 2003;26:484-490.
159. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C: A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-323.
160. Mittman N, Khanna R, Rani S, Chattopadhyay J, Avram MM: Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover study. Kidney Int Suppl 2006;S64-S67.
161. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;36:550-561.
162. Tan AU, Jr., Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-323.
163. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-890.
164. Dennis VC, Albertson GL: Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother 2006;40:1955-1965.
165. Maung HM, Elangovan L, Frazao, JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-543.
166. Yasuda M, Akiba T, Nihei H: Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. Am J Kidney Dis 2003;41:S108-S111.
167. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K: Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38:S147-S151.
168. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y: Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998;32: 238-246.
169. Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R: [Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients]. Clin Calcium 2006;16:847-851.
170. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E: Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283-1288.
171. Saarem K, Pedersen JI: 25-Hydroxylation of 1 alpha-hydroxyvitamin D-3 in rat and human liver. Biochim Biophys Acta 1985;840:117-126.
172. Holmberg I, Berlin T, Ewerth S, Bjorkhem I: 25-Hydroxylase activity in subcellular fractions from human liver. Evidence for different rates of mitochondrial hydroxylation of vitamin D2 and D3. Scand J Clin Lab Invest 1986;46:785-790.
173. Chalmers TM, Hunter JO, Davie MW, Szaz KF, Pelc B, Kodicek E: 1-Alpha-hydroxycholecalciferol as a substitute for the kidney hormone 1,25-dihydroxycholecalciferol in chronic renal failure. Lancet 1973;2:696-699.
174. Madsen S: Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Acta Med Scand Suppl 1980;638:3-120.
175. Henderson RG, Russell RG, Ledingham JG, Smith R, Oliver DO, Walton RJ, Small DG, Preston C, Warner GT: Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1974;1:379-384.
176. Toffolon EP, Pechet MM, Isselbacher K: Demonstration of the rapid action of pure crystalline 1 alpha-hydroxy vitamin D3 and 1 alpha,25-dihydroxy vitamin D3 on intestinal calcium uptake. Proc Natl Acad Sci U S A 1975;72:229-230.
177. Napoli JL, Fivizzani MA, Schnoes HK, DeLuca HF: 1 alpha-hydroxy-25-fluorovitamin D3: a potent analogue of 1 alpha,25- dihydroxyvitamin D3. Biochemistry 1978;17:2387-2392.
178. Nielsen PK, Feldt Rasmussen U Olgard K. A direct inhibitory effect of 1a-hydroxy-vitamin D3 on PTH secretion from bovine parathyroid glands. J.Am.Soc.Nephrol. 8, 578A. 1997.
179. Norman AW, Adams D, Collins ED, Okamura WH, Fletterick RJ: Three-dimensional model of the ligand binding domain of the nuclear receptor for 1alpha,25-dihydroxy-vitamin D(3). J Cell Biochem 1999;74:323-333.
180. Ahmed KY, Varghese Z, Wills MR, Meinhard EA, Moorhead JF: Longterm effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Lancet 1978;1:629-632.
181. Madsen S, Olgaard K: L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure. Acta Med Scand 1976;200:1-5.
182. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry SG, Norman AW: Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy- vitamin D3 in man. J Clin Invest 1976;57:1540-1547.
183. Drueke TB: Medical management of secondary hyperparathyroidism in uremia. Am J Med Sci 1999;317:383-389.
184. el Reshaid K, el Reshaid W, Sugathan T, al Mohannadi S, Sivanandan R: Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997;17:505-510.
185. Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O: Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Clin Nephrol 1991;35:72-77.
186. Ohno J, Kubota M, Hirasawa Y, Suzuki M, Mimura N, and Minamikata. clinical evaluation of 1 -hydroxycholecalciferol and 1,25- dihydroxycholecalciferol in the treatment of renal osteodystrophy. 847-852. 1982. Vitamin D, Chemical, Biochemical and Clinical endocrinology of calcium metabolism, Proceeding of the 5th workshop of vitamin D.
187. Seino Y, Tanaka H, Yamaoka K, Yabuuchi H: Circulating 1 alpha,25-dihydroxyvitamin D levels after a single dose of 1 alpha,25-dihydroxyvitamin D3 or 1 alpha-hydroxyvitamin D3 in normal men. Bone Miner 1987;2:479-485.
188. 3 levels after the administration of calcitriol and alfacalcidol. 314-315. 1991. Gene Regulation Structure - Function analysis and clinical application, Proceedings of the Eight Workshop on Vitamin D. Paris, France.
189. Papapoulos SE, Berg H, Frolich M, Valentijn RM: Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis. Nephrol Dial Transplant 1988;3:647-650.
190. Salusky, I. B., Goodman, W. G., Horst, R., Segre, G. V., Norris, K. C., and Coburn, J. W. Plasma Kinetics of intravenous calcitriol in normal and dialysed subjects and acute effect on serum nPTH levels. 781-782. 1988. Vitamin D. Molecular, Cellular and Clinical Endocrinology, Proceedings of the 7th workshop on Vitamin D.
191. Ichikawa F, Sato K, Nanjo M, Nishii Y, Shinki T, Takahashi N, Suda T: Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1 alpha-hydroxyvitamin D3 into 1 alpha,25-dihydroxyvitamin D3. Bone 1995;16:129-135.
192. Anderson PH, Atkins GJ, Findlay DM, Oloughlin PD, Welldon K, Vincent C, Morris HA: RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)(2)D(3) synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. J Steroid Biochem Mol Biol 2006.
193. Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int Suppl 1990;29:S54-S61.
194. Fischer ER, Harris DC: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993;40:216-220.
195. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000;57:282-292.
196. Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour JP: Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 1994;45:245-252.
197. Fischer JA, Binswanger U, Blum JW: The acute parathyroid hormone response to changes in ionized calcium during phosphate infusions in the cow. Eur J Clin Invest 1973;3:151-155.
198. McLean, F. C. and Hastings, A. B. The state of calcium in the fluids of the body. J.Biol.Chem. 108, 285-322. 1935.
199. Berridge MJ, Lipp P, Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21.
200. Madsen S, Olgaard K: Evaluation of a new automatic calcium ion analyzer. Clin Chem 1977;23:690-694.
201. Daugaard H: Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats. Dan Med Bull 1996;43:203-215.
202. Habener JF, Rosenblatt M, Potts JT, Jr.: Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 1984;64:985-1053.
203. Berson SA, Yalow RS: Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968;28:1037-1047.
204. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004;43:558-565.
205. Simon M, Cuan J: Diagnostic utility of C-terminal parathyrin measurement as compared with measurements of N-terminal parathyrin and calcium in serum. Clin Chem 1980;26:1672-1676.
206. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT, Jr., Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-1367.
207. Daugaard H, Egfjord M, Olgaard K: Metabolism of intact parathyroid hormone in isolated perfused rat liver and kidney. Am J Physiol 1988;254:E740-E748.
208. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26:622-631.
209. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/ large C-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:1460-1468.
210. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 1975;41:339-345.
211. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA: Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000;58:1440-1449.
212. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M: Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-532.
213. Hruska KA, Saab G, Chaudhary LR, Quinn CO, Lund RJ, Surendran K: Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 2004;24:25-38.
214. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-3929.
215. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-809.
216. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D'Amour P: Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46:697-703.
217. Inomata N, Akiyama M, Kubota N, Juppner H: Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 1995;136:4732-4740.
218. Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR: Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 2001;142:916-925.
219. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753-761.
220. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P: Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001;142:1386-1392.
221. Divieti P, John MR, Juppner H, Bringhurst FR: Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002;143:171-176.
222. Lucas PA, Woodhead JS, Brown RC: Vitamin D3 metabolites in chronic renal failure and after renal transplantation. Nephrol Dial Transplant 1988;3:70-76.
223. Dusso A, Brown A, Slatopolsky E: Extrarenal production of calcitriol. Semin Nephrol 1994;14:144-155.
224. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A: Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999;55:2169-2177.
225. Elder GJ: Vitamin D levels, bone turnover and bone mineral density show seasonal variation in patients with chronic kidney disease stage 5. Nephrology (Carlton) 2007;12:90-94.
226. Cannata-Andia JB, Gomez AC: Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 2002;17:1875-1878.
227. Reinhardt TA, Horst RL, Orf JW, Hollis BW: A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 1984;58: 91-98.
228. Ferreira A, Drueke TB: Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci 2000;320:85-89.
229. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxy-terminal propeptide of human type I procollagen. Clin Chem 1990;36: 1328-1332.
230. Goodman WG, Duarte ME: Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metab 1991;17: 221-232.
231. de Wolff FA: Toxicological aspects of aluminum poisoning in clinical nephrology. Clin Nephrol 1985;24 Suppl 1:S9-14.
232. Twardowski, Z., Nolph, K. D., Khanna, R., Prowant, B., Ryan, L., and Moore, H. Peritoneal equilibrium test. Perit.Dial.Bull. 3, 138-147. 1987.
233. Adams JE: Dialysis bone disease. Semin Dial 2002;15:277-289.
234. Schwarz C, Sulzbacher I, Oberbauer R: Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006;36 Suppl 2:13-22.
235. Ritchie WG, Winney RJ, Davison AM, Robson JS: Periosteal new bone formation developing during haemodialysis for chronic renal failure. Br J Radiol 1975;48:656-661.
236. Falbo SE, Sundaram M, Ballal S, Domoto D, Martin K: Clinical significance of erosive azotemic osteodystrophy: a prospective masked study. Skeletal Radiol 1999;28:86-89.
237. Raggi P, Bellasi A: Clinical assessment of vascular calcification. Adv Chronic Kidney Dis 2007;14:37-43.
238. Dear J, Brookes J, Mansell M, Laing C: Calciphylaxis. Lancet 2003;362:1707.
239. Bellasi A, Ferramosca E, Muntner P, Ratti C, Wildman RP, Block GA, Raggi P: Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006;70:1623-1628.
240. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J: Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004;43:566-571.
241. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R, Parfitt AM: Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 1998;9:1225-1233.
242. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000;13:437-443.
243. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G: Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218-226.
244. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-293.
245. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-1121.
246. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA: Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 2002;39:843-849.
247. Madsen, S. and Olgaard, K. Long-term trial of 1a-hydroxycholecalciferol in adults with chronic renal failure. Eur.J.Clin.Pharmacol. 13, 401-408. 1978.
248. Lind L, Wengle B, Wide L, Wrege U, Ljunghall S: Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. A pilot study. Nephron 1988;48: 296-299.
249. 3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int 1988;43:213-218.
250. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F: Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001;12:1242-1248.
251. de Francisco AL, Fresnedo GF, Rodrigo E, Pinera C, Amado JA, Arias M: Parathyroidectomy in dialysis patients. Kidney Int Suppl 2002;161-166.
252. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323:421-422.
253. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:1710-1721.
254. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF: Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992;267:20082-20086.
255. Canaff L, Hendy GN: Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002;277:30337-30350.
256. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-1355.
257. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989;36:1093-1098.
258. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F: The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991;2:1014-1020.
259. Albaaj F, Hutchison A: Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003;63:577-596.
260. Brown AJ, Finch J, Slatopolsky E: Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279-284.
261. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM: Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 2005;25:591-595.
262. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84:728-732.
263. Kubrusly M, Gagne ER, Urena P, Hanrotel C, Chabanis S, Lacour B, Drueke TB: Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 1993;44:551-556.
264. Sjoden G, Smith C, Lindgren U, DeLuca HF: 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178:432-436.
265. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-279.
266. Mazess RB, Elangovan L: A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol 2003;59:319-325.
267. Fournier A, Moriniere PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, El Esper N, Ghazali A, Boudailliez B: 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 1995;71:254-283.
268. Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW: "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 1987;32:89-95.
269. Carozzi S, Nasini MG, Schelotto C, Caviglia PM, Santoni O, Pietrucci A: Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients. ASAIO J 1992;38:M593-M595.
270. Wadhwa NK, Suh H, Howell N, Cabralda T, Sokunbi D, Solomon M: Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients. Adv Perit Dial 1993;9:260-263.
271. Rolla D, Paoletti E, Marsano L, Mulas D, Peloso G, Cannella G: Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int 1993;13:118-121.
272. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, Slatopolsky E: The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987;31:795-799.
273. Arora N, Sandroni S, Moles K: Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol. Adv Perit Dial 1992;8:62-64.
274. Jones CL, Vieth R, Spino M, Ledermann S, Kooh SW, Balfe J, Balfe JW: Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. Clin Nephrol 1994;42:44-49.
275. Juergensen P, Santacroce S, Mooraki A, Cooper K, Finkelstein FO, Kliger AS: Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients. Adv Perit Dial 1994;10:259-260.
276. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations. Am J Kidney Dis 1992;19:540-545.
277. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M: Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998;13:1234-1241.
278. Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J: High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients. Nephrol Dial Transplant 1989;4:105-109.
279. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989;36:897-903.
280. Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993;43:630-640.
281. Sperschneider H, Gunther K, Marzoll I, Kirchner E, Stein G: Calcium carbonate (CaCO3): an efficient and safe phosphate binder in haemodialysis patients? A 3-year study. Nephrol Dial Transplant 1993;8:530-534.
282. Fernandez E, Borras M, Pais B, Montoliu J: Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol 1995;6:132-135.
283. Fabrizi F, Bacchini G, Di Filippo S, Pontoriero G, Locatelli F: Intradialytic calcium balances with different calcium dialysate levels. Effects on cardiovascular stability and parathyroid function. Nephron 1996;72: 530-535.
284. Brown CB, Hamdy NA, Boletis J, Boyle G, Beneton MN, Charlesworth D, Kanis JA: Osteodystrophy in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993;13 Suppl 2:S454-S460.
285. Pagliari B, Baretta A, De C, V, Sama F, Cantaluppi A, Martis L, Imbasciati E: Short-term effects of low-calcium dialysis solutions on calcium mass transfer, ionized calcium, and parathyroid hormone in CAPD patients. Perit Dial Int 1991;11:326-329.
286. Merchant MR, Hutchinson AJ, Butler SJ, Boulton H, Hintchliffe R, Gokal R: Calcium, magnesium mass transfer and lactate balance study in CAPD patients with reduced calcium/magnesium and high lactate dialysis fluid. Adv Perit Dial 1992;8:365-368.
287. Bro S, Brandi L, Olgaard K: High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone. Nephrol Dial Transplant 1996;11:1586-1591.
288. Weinreich T, Passlick-Deetjen J, Ritz E: Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Am J Kidney Dis 1995;25:452-460.
289. Rudnicki M, Hojsted J, Petersen LJ, Sorensen HA, Hyldstrup L, Transbol I: Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study. Nephron 1993;65:369-374.
290. Saisu T, Wakabayashi Y, Yamada K, Shigematsu T, Goto S, Nishimura M, Miura Y, Nakano H, Moriya H: Effect of low-calcium hemodialysate on bone metabolism. J Bone Miner Metab 2000;18:57-62.
291. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993; 44:860-866.
292. Moriniere P, Cohen-Solal M, Belbrik S, Boudailliez B, Marie A, Westeel PF, Renaud H, Fievet P, Lalau JD, Sebert JL: Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989;53:93-101.
293. Coburn JW: Mineral metabolism and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int Suppl 1993;40:S92-100.
294. Mucsi I, Hercz G: Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 1999;317:405-409.
295. Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, Almaden Y, Felsenfeld AJ: Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 2000;15:927-935.
296. Hutchison AJ, Freemont AJ, Boulton HF, Gokal R: Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992;7:1219-1225.
297. Delmez JA: Removal of phosphorus by peritoneal dialysis. Perit Dial Int 1993;13 Suppl 2:S461-S463.
298. Parfitt AM, Simon LS, Villanueva AR, Krane SM: Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2: 427-436.
299. Hasling C, Eriksen EF, Melkko J, Risteli L, Charles P, Mosekilde L, Risteli J: Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J Bone Miner Res 1991;6:1295-1300.
300. Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, Pasquali M, Perruzza I, Sardella D, Spurio A: Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 1992;12:246-251.
301. Hamdy NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, Kanis JA: Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994;9:511-516.
302. Coen G, Mazzaferro S, De Antoni E, Chicca S, DiSanza P, Onorato L, Spurio A, Sardella D, Trombetta M, Manni M,.: Procollagen type 1 Cterminal extension peptide serum levels following parathyroidectomy in hyperparathyroid patients. Am J Nephrol 1994;14:106-112.
303. Malluche HH, Faugere MC, Fanti P, Price PA: Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984;26:869-874.
304. Delmas PD, Christiansen C, Mann KG, Price PA: Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res 1990;5:5-11.
305. Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R, Buccianti G: Bone mass status in different degrees of chronic renal failure. Bone 1992;13:225-228.
306. Madsen S, Olgaard K, Ladefoged J: Bone mineral content in chronic renal failure during long-term treatment with 1alpha-hydroxycholecalciferol. Acta Med Scand 1978;203:385-389.
307. Nishitani H, Yamakawa M, Nishizawa Y, Morii H: Bone mineral loss in patients on maintenance hemodialysis with hyperphosphatemia treated with 1 alpha-hydroxycholecalciferol and calcium carbonate. J Nutr Sci Vitaminol (Tokyo) 1991;37 Suppl:S113-S118.
308. Dansk Nefrologisk Selskab: Henrik Daugaard, James Heaf, Preben Joffe, Ewa Lewin, Søren Madsen, Marianne Rix, Klaus Olgaard: Forstyrrelser i knogle og mineraloms'tningen ved kronisk nyresygdom - guidelines for diagnostik og behandling. K/DOQI guidelines konverteret til danske forhold. Dansk Nefrologisk Selskab 2005.
309. el Hajj FG, Chen CJ, Rivkees SA, Marynick SP, Stock J, Pallotta JA, Brown EM: Calcium-dependent release of N-terminal fragments and intact immunoreactive parathyroid hormone by human pathological parathyroid tissue in vitro. J Clin Endocrinol Metab 1989;69:860-867.
310. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-4290.
311. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H: Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003;18:759-768.
312. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D: PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002;40:348-354.
313. Godber IM, Parker CR, Lawson N, Hitch T, Porter CJ, Roe SD, Cassidy MJ, Hosking DJ: Comparison of intact and 'whole molecule' parathyroid hormone assays in patients with histologically confirmed postrenal transplant osteodystrophy. Ann Clin Biochem 2002;39:314-317.
314. Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, Fukagawa M: Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001;38:S172-S174.
315. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003;63:1801-1808.
316. Napoli JL, Pramanik BC, Royal PM, Reinhardt TA, Horst RL: Intestinal synthesis of 24-keto-1,25-dihydroxyvitamin D3. A metabolite formed in vivo with high affinity for the vitamin D cytosolic receptor. J Biol Chem 1983;258:9100-9107.
317. Shigematsu T, Kawaguchi Y, Unemura S, Yamamoto H, Momose M, Yokoyama K, Wakabayashi Y, Ikeda M, Hasegawa T, Sakai O: Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol. Intern Med 1993;32:695-701.
318. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G, Westin G: 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 2002;87:2967-2972.
319. Schmitt CP, Schaefer F, Huber D, Zahn I, Veldhuis JD, Ritz E, Mehls O: 1,25(OH)2-vitamin D3 reduces spontaneous and hypocalcemia-stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 1998;9:54-62.
320. Gallacher SJ, Cowan RA, Fraser WD, Logue FC, Jenkins A, Boyle IT: Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man. Eur J Endocrinol 1994;130:141-145.
321. Saha H, Pietila K, Mustonen J, Pasternack A, Morsky P: Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients. Clin Nephrol 1992;38:145-148.
322. Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O: No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int 2000;58:981-988.
323. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN: Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol 1994;41:364-369.
324. Koike N, Ichikawa F, Nishii Y, Stumpf WE: Sustained osteoblast nuclear receptor binding of converted 1alpha, 25-dihydroxyvitamin D3 after administration of 3H-1alpha-hydroxyvitamin D3: a combined receptor autoradiography and radioassay time course study with comparison to 3H-1alpha, 25-dihydroxyvitamin D3. Calcif Tissue Int 1998;63:391-395.
325. Procsal DA, Okamura WH, Norman AW: Structural requirements for the interaction of 1 alpha, 25-(OH) 2- vitiamin D3 with its chick interestinal receptor system. J Biol Chem 1975;250:8382-8388.
326. Hsu CH, Patel S, Buchsbaum BL: Calcitriol metabolism in patients with chronic renal failure. Am J Kidney Dis 1991;17:185-190.
327. Upton RA, Knutson JC, Bishop CW, LeVan LW: Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18:750-758.
328. Ketteler M, Gross ML, Ritz E: Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 2005;S120-S127.
329. Salusky IB: A new era in phosphate binder therapy: What are the options? Kidney Int Suppl 2006;S10-S15.
330. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007.
331. Freemont AJ: Lanthanum carbonate. Drugs Today (Barc) 2006;42:759-770.
332. Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
333. Brown AJ, Finch J, Takahashi F, Slatopolsky E: Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol 2000;11:2088-2094.
334. Kamimura S, Gallieni M, Kubodera N, Nishii Y, Brown AJ, Slatopolsky E, Dusso A: Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. Endocrinology 1993;133:2719-2723.
335. Miyamoto Y, Shinki T, Ohyama Y, Kasama T, Iwasaki H: Regulation of vitamin D-responsive gene expression by fluorinated analogs of calcitriol in rat osteoblastic ROB-C26 cells. J Biochem (Tokyo) 1995;118: 1068-1076.
336. Brown AJ, Ritter CS, Knutson JC, Strugnell SA: The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006;21:644-650.
337. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Multicenter Study. J Am Soc Nephrol 2005;16:800-807.
338. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865.
339. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.